MedTrace Logo

Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

NCT04915586 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-06-07

No results posted yet for this study

Summary

The aim of this study was to assess the efficacy of the modified regimen short duration intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme Hoffmann-La Roche Ltd) in patients with pleural infection.

Conditions

  • Loculated Empyema

Interventions

DRUG

Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg

Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours

Sponsors & Collaborators

  • National University of Malaysia

    lead OTHER

Principal Investigators

  • Mohamed Faisal Abdul Hamid · Associate Professor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04915586 on ClinicalTrials.gov